A robust pipeline of TRuC-T cell therapies for solid and hematologic cancers

We are developing a wide range of cell therapies for solid tumors as well as blood cancers by targeting a number of different surface antigens on cancer cells that have beneficial expression characteristics. We are also supplementing our basic TRuC-T cell format with innovative enhancements to combat the hostile tumor microenvironment in case certain cancer indications prove more resistant.

Our most advanced program, gavo-cel, targets tumors that express the protein mesothelin, including ovarian cancer, non-small cell lung cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Our preclinical programs are a combination of additional novel targets, technological enhancements for autologous therapies, and the expansion of TRuC-T cells into autoimmune diseases.

For more information on the full Adaptimmune pipeline, visit adaptimmune.com.

  • Pipeline
  • Innovations in Progress
indications
preclinical
phase 1
phase 2
phase 3

Solid Tumors

gavo-cel
Target: Mesothelin
Ovarian cancer, NSCLC, MPM, Cholangiocarcinoma
Indications: Ovarian cancer, NSCLC, MPM, Cholangiocarcinoma
Progress: Phase 2
TC-510
(PD-1 Switch)
Target: Mesothelin
MPM, Ovarian cancer, Pancreatic cancer, Colorectal cancer, TBNC
Indications: MPM, Ovarian cancer, Pancreatic cancer, Colorectal cancer, TBNC
Progress: Phase 1
TC-520
Target: CD70
Solid Tumors, Hematological Malignancies
Indications: Solid Tumors, Hematological Malignancies
Progress: Preclinical

NSCLC: non-small cell lung cancer; MPM: malignant pleural/peritoneal mesothelioma; aALL: adult acute lymphoblastic leukemia; DLBCL: diffuse large B-cell lymphoma; NHL: other non-Hodgkin lymphoma (NHL) subtypes including follicular lymphoma (FL), mantle cell lymphoma (MCL), primary mediastinal B-cell lymphoma (PMBCL)

Innovations in Progress

We continue to broaden our platform through internal research and collaboration with leading academic laboratories and industry partners. These innovations fall into three broad categories:

Novel Targets

Due to the TRuC platform’s versatility, we have the capability to target many different cancer antigens. We are focused on the discovery and validation of novel targets to broaden the reach of TRuC-T cells in solid tumors and hematologic cancers. Our strategy for determining the right target is based on:

  • Expression profile of the tumor antigen
  • Scientific evidence and validation of the tumor antigen
  • Evaluation of patient population of target indications, market landscape, and competition
  • Clinical path forward

Enhancements

We are developing:

  • TRuC-T cells with switch receptors which will be equipped to turn a suppressive signal from the tumor microenvironment into a positive. Our lead switch receptor is TC-510, a PD-1:CD28 switch receptor, and we are also developing further activating and kill switches based on activating and inhibitory concepts for our TRuCs.
  • Several enhancements to control “off-tumor” activity and counter the immunosuppressive microenvironment of solid tumors. These include mechanisms such as those that block a key cancer defense known as the PD-1/PD-L1 pathway and cells that secrete IL-15 which promotes the formation of memory T cells and triggers survival and differentiation signals in the absence of antigen stimulation.

Novel Targets

Due to the TRuC platform’s versatility, we have the capability to target many different cancer antigens. We are focused on the discovery and validation of novel targets to broaden the reach of TRuC-T cells in solid tumors and hematologic cancers. Our strategy for determining the right target is based on:

  • Expression profile of the tumor antigen
  • Scientific evidence and validation of the tumor antigen
  • Evaluation of patient population of target indications, market landscape, and competition
  • Clinical path forward
learn about our science